Biotech Startups

KBP Biosciences is a biotechnology research and development organization that discovers and develops innovative therapeutic drugs for unmet medical needs using an integrated discovery and development platform.

2 investors

Quaero Life (Jiaxing Kaishi Biotechnology) develops, manufactures, and services in vitro diagnostic (IVD) instruments and life science consumables, providing automated and intelligent solutions for the IVD industry. Based in Jiaxing, Zhejiang, China, the company operates R&D centers and manufacturing plants across China, North America, and Japan.

2 investors

TYK Medicines (同源康) is a Chinese biopharmaceutical company focused on discovering and developing innovative small-molecule drugs, with a platform for designing and screening targeted-therapy compounds. Its pipeline includes EGFR-targeting treatments for non-small cell lung cancer and brain metastases.

2 investors

Stonewise builds an AI-powered small-molecule drug design platform using multimodal 3D molecular generation models for pharmaceutical research and development. The company leverages molecular dynamics simulation and machine learning to assist drug discovery teams in structure analysis and molecular information extraction.

2 investors

EXORPHIA develops extracellular vesicle (EV) technology for assisted reproductive medicine, focusing on cell-free IVF culture medium additives to improve embryo development and fertilization success rates. The company targets fertility clinics and academic institutions in reproductive medicine.

2 investors

iXgene develops regenerative medicine therapies using genome-edited induced pluripotent stem cells (iPSCs) to treat conditions including glioblastoma and traumatic brain injury. The company focuses on gene and cell therapies derived from genetically engineered stem cells.

2 investors

LEP (株式会社LEP) develops applications based on its proprietary bioluminescent protein technology to illuminate homes and cities, pursuing agriculture, exhibition, and energy business lines. The company is based in Osaka, Japan.

2 investors

Liquid Mine develops MyRD®, a liquid biopsy-based genomic testing system that creates personalized diagnostic tests for leukemia and other cancers by analyzing individual patient genetic mutations. The company aims to advance precision medicine in oncology by making genomic testing more accessible, particularly in Japan, through collaboration with Tokyo University's Institute of Medical Science.

2 investors

Mitate Zepto Technica develops specialized semiconductor and computing hardware for genome analysis, including custom processors, accelerator boards, and supercomputers that perform genomic sequencing at significantly higher speeds and lower costs than conventional systems.

2 investors

Chiome is a Japanese biotech venture that discovers and develops antibody drugs targeting unmet medical needs. It works to create drug candidates and build product pipelines through collaboration with external institutions.

2 investors

Kino Pharma is a Japan-based company with a Tokyo headquarters and a Kyoto research laboratory. The page provides only corporate location information and does not describe the company's products or services.

2 investors

TWOCELLS (株式会社ツーセル) is a regenerative medicine venture developing therapies and products based on mesenchymal stem cells (MSCs), including its gMSC series for cartilage regeneration, along with serum-free culture media (STK series) and consulting services. Founded as a Hiroshima University spin-off, it also licenses its technology to pharmaceutical partners.

2 investors

Kabushiki Kaisha PhoenixBio is a Japanese biotechnology company established in 2002. It operates subsidiaries in the United States, including PhoenixBio USA Corporation and CMHL Consortium LLC.

2 investors

MedRx is a Japanese pharmaceutical company developing new drugs based on transdermal delivery technologies such as its ILTS and NCTS platforms and microneedle arrays. It is a publicly listed company focused on creating novel therapeutics for patients with various diseases.

2 investors

Ribomic is a company with a U.S. subsidiary engaged in research and development, including pharmaceutical and research-ethics-related activities. The page describes its compliance program, ethics committee, employee training, whistleblower hotline, and management of public research funding.

2 investors

Reborna Biosciences is a Japanese biotech company that researches and develops RNA-targeting small-molecule drugs for hereditary rare diseases. Founded in 2018, it operates from the Shonan iPark research campus.

2 investors

Renascience is a Japanese biotechnology company that develops pharmaceutical and medical projects. It presents its business model, project pipeline progress, and corporate/IR information.

2 investors

Kyoto Drug develops novel therapeutic drugs for rare and difficult-to-treat ocular diseases including retinal artery occlusion and retinitis pigmentosa, using a new small-molecule compound (KUS agent) based on research from Kyoto University.

2 investors

Tigermed is a contract research organization (CRO) offering full-service clinical development support to the global biopharmaceutical and medical device industries, covering small molecules, biologics, vaccines, and medical devices. Founded in 2004 and publicly listed (300347.SZ / 3347.HK), it provides services including clinical monitoring, regulatory affairs, data management, and site management.

2 investors

Wuhan Oryzogen is a biopharmaceutical company that develops plant-based recombinant protein expression technology and products, having built an industrialization and quality-assurance system for plant-derived biologic drugs in China. It operates a rice-endosperm-cell protein expression platform and a protein purification platform for drug and product development.

2 investors

C&R Research is a contract research organization providing end-to-end clinical trial services, including regulatory and non-regulatory trials as well as multinational studies. It has conducted around 1,800 clinical trials, including 79 global multinational trials, over 29 years.

1 investor

Inner Resource develops and operates web content platforms and systems, offering services in content planning, production, management, and advertising-related operations.

1 investor

TL Genomics develops in vitro diagnostic medical products and healthcare testing services, focusing on bone marrow transplant testing, chromosome analysis for disease risk and fertility assessment, and related medical services.

1 investor

1517 is an early-stage venture capital fund and community that backs college dropouts, uncredentialed founders, and deep-tech scientists from the idea/R&D phase through the seed stage. Founded by cofounders of the Thiel Fellowship, it invests across software, hardware, and deep tech, and also runs a grant program and a global community of hackers, makers, and scientists.

1 investor